Bacil Pharma Income Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Selling, General & Admin	0.49	1.38	0.99	0.86	0.6
Other Operating Expenses	1.96	1.14	0.88	0.91	0.95
Operating Expenses	2.45	2.53	1.89	1.8	1.59
Operating Income	-2.45	-2.53	-1.89	-1.8	-1.59
Interest Expense	-	-0.01	-0.01	-0.01	-0.01
Interest & Investment Income	-	0.83	0.3	0.29	0.58
Other Non Operating Income (Expenses)	12.35	0.4	-	-	-
EBT Excluding Unusual Items	9.9	-1.31	-1.6	-1.52	-1.02
Gain (Loss) on Sale of Investments	-	5.38	1.01	0.5	-0.63
Gain (Loss) on Sale of Assets	-	-	-	-	-36.95
Pretax Income	9.9	4.08	-0.59	-1.02	-38.6
Income Tax Expense	-5.65	0.03	0	-0	-0
Net Income	15.56	4.04	-0.59	-1.02	-38.6
Net Income to Common	15.56	4.04	-0.59	-1.02	-38.6
Net Income Growth	284.92%	-	-	-	-
Shares Outstanding (Basic)	14	6	6	6	6
Shares Outstanding (Diluted)	14	6	6	6	6
Shares Change (YoY)	121.94%	6.92%	-1.47%	1.71%	0.99%
EPS (Basic)	1.11	0.64	-0.10	-0.17	-6.55
EPS (Diluted)	1.11	0.64	-0.10	-0.17	-6.55
EPS Growth	73.44%	-	-	-	-
Free Cash Flow	7.12	4.01	-0.03	-1.48	-40.09
Free Cash Flow Per Share	0.51	0.64	-0.01	-0.25	-6.80
EBITDA	-2.44	-2.53	-1.87	-1.77	-1.55
D&A For EBITDA	0.01	0.01	0.02	0.03	0.04
EBIT	-2.45	-2.53	-1.89	-1.8	-1.59
Effective Tax Rate	-	0.85%	-	-	-
Revenue as Reported	12.35	6.61	1.31	1.15	0.58